Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.66 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129801 | 0.88 | CYP4F2 (0.71) | CYP4F2CYP4A11RAB9ANPC1MEP1B | |
| SCHEMBL5544912 | 0.87 | CYP4F2 (0.71) | CYP4F2CYP4A11RAB9ANPC1MEP1B | |
| SCHEMBL3813671 | 0.87 | LMNA (0.60) | CYP4F2CYP4A11RAB9ANPC1MAPT | |
| SCHEMBL128387 | 0.85 | CYP4F2 (0.72) | CYP4F2CYP4A11RAB9ANPC1MEP1B | |
| SCHEMBL2089661 | 0.85 | CYP4F2 (0.68) | CYP4F2CYP4A11RAB9ANPC1MEP1B | |
| SCHEMBL110276 | 0.84 | CYP4F2 (0.65) | CYP4F2CYP4A11RAB9ANPC1ALDH1A1 | |
| SCHEMBL12035616 | 0.83 | CYP4F2 (0.75) | CYP4F2CYP4A11RAB9ANPC1MEP1B | |
| SCHEMBL2450193 | 0.83 | LOXL2 (0.71) | CYP4F2CYP4A11RAB9ANPC1MEP1B | |
| SCHEMBL1198044 | 0.83 | CYP4F2 (0.66) | CYP4F2CYP4A11RAB9ANPC1MEP1B | |
| SCHEMBL4508966 | 0.83 | CYP4F2 (0.66) | CYP4F2CYP4A11RAB9ANPC1MEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10065926-B2 | Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-09-04 | — | — | US | claimed |
| EP-3051946-B1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2017-11-29 | — | — | EP | claimed |
| US-20160237035-A1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-08-18 | — | — | US | claimed |
| EP-3051946-A1 | USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | Bayer CropScience Aktiengesellschaft (DE) | 2016-08-10 | — | — | EP | claimed |
| WO-2015049351-A1 | USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AG (DE) | 2015-04-09 | — | — | WO | claimed |
| US-10065926-B2 | Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-09-04 | — | — | US | disclosed |
| EP-3051946-B1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2017-11-29 | — | — | EP | disclosed |
| US-9631048-B2 | Sulfonium compounds, their preparation and use | BASF SE (DE) | 2017-04-25 | — | — | US | disclosed |
| CN-104379628-B | Sulfonium compound, it prepares and application thereof | 巴斯夫欧洲公司 | 2016-11-16 | — | — | CN | disclosed |
| US-20160237035-A1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-08-18 | — | — | US | disclosed |
| EP-3051946-A1 | USE OF SUBSTITUTED DIHYDRO-OXINDOLYL SULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | Bayer CropScience Aktiengesellschaft (DE) | 2016-08-10 | — | — | EP | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065926-B2 | Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants | SQOR, DHPS, QDPR | CYP4F2 337/4885CYP4A11 452/4885RAB9A 1746/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CYP4F2 954/4885CYP4A11 1804/4885RAB9A 2824/4885 |
| US-20160237035-A1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | SQOR, DHPS, QDPR | CYP4F2 337/4885CYP4A11 452/4885RAB9A 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.